Success Metrics

Completion Rate
0%(0/1)
Active Trials
0(0%)
Terminated
1(33%)

Phase Distribution

Ph phase_2
2
67%
Ph phase_3
1
33%

Phase Distribution

0

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
2(66.7%)
Phase 3Large-scale testing
1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Terminated(1)
Other(1)

Detailed Status

unknown1
Not yet recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Phase 22 (66.7%)
Phase 31 (33.3%)

Trials by Status

unknown133%
not_yet_recruiting133%
terminated133%

Recent Activity

0 active trials
Showing 3 of 3
not_yet_recruitingphase_2

SBRT Combined With Nimotuzumab and Mono-chemotherapy in Locally Advanced Pancreatic Cancer

NCT06422156
terminatedphase_3

Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBC

NCT03905343
unknownphase_2

Combination of Anti-PD-1 Antibody and Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma

NCT04413734

Clinical Trials (3)

Showing 3 of 3 trials
NCT06422156Phase 2

SBRT Combined With Nimotuzumab and Mono-chemotherapy in Locally Advanced Pancreatic Cancer

Not Yet Recruiting
NCT03905343Phase 3

Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBC

Terminated
NCT04413734Phase 2

Combination of Anti-PD-1 Antibody and Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma

Unknown

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3